Edwards Lifesciences Reports Q4 2025 Earnings Results

Edwards Lifesciences Corporation (NYSE: EW) released its fourth quarter 2025 earnings results on February 10, 2026, filing an 8-K with the Securities and Exchange Commission.

Key Numbers

The medical device company, which specializes in heart valves and critical care technologies, reported its Q4 2025 results via press release. Based on available XBRL financial data, Edwards Lifesciences showed full-year 2025 earnings per share of $1.83 and net income of $1.07 billion for the fiscal year.

The company's recent quarterly performance showed earnings per share of $0.50 in the third quarter of 2025, with quarterly net income of $290 million. Earlier in 2025, the company reported Q2 earnings per share of $1.18 with net income of $690 million.

[Note: The actual Q4 2025 earnings figures, revenue, and comparison to analyst estimates would typically be included here from the press release Exhibit 99.1, which was not provided in the filing content.]

What Management Said

[Note: Management commentary from CEO Bernard Zovighian and CFO Scott B. Ullem would typically be included here from the earnings press release and conference call transcript, which were not provided in the filing content.]

The company's leadership team likely addressed key topics including performance of the Transcatheter Aortic Valve Replacement (TAVR) platform, growth in emerging markets, and progress on new product launches during the earnings call.

What to Watch

Investors should monitor several key factors for Edwards Lifesciences going forward:

• TAVR Market Growth: The company's flagship transcatheter heart valve products remain the primary growth driver

• Pipeline Development: Progress on next-generation valve technologies and critical care innovations

• International Expansion: Penetration in underdeveloped markets where structural heart disease treatment adoption is increasing

• Competitive Dynamics: Market share trends as competitors advance their own transcatheter valve programs

• 2026 Guidance: The company's outlook for the new fiscal year and any updates to long-term growth targets

Edwards Lifesciences continues to be a leader in the structural heart disease market, with its innovative therapies addressing significant unmet medical needs. The fourth quarter results cap off fiscal 2025 for the Irvine, California-based medical technology company.

*Source: Edwards Lifesciences Corporation Form 8-K filed with the SEC on February 10, 2026*

— StockCliff Research